Start activity
Videos Take ACPE Test
Paediatric Neurology, Stroke, Rare Diseases CE/CME accredited

A visually engaging discussion designed to emulate a ‘live’ panel experience and provide clinicians with practical expert insights to address their clinical challenges. Useful tips below will show how to navigate the activity. Close

Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy

  • Downloads including slides are available for this activity in the Toolkit
Learning Objectives

After watching this activity, participants should be better able to:

  • Summarize the various manifestations and multiple complications of SCD
  • Appraise the practical considerations for the multidisciplinary management of SCD complications
  • Interpret the clinical data for established and recently approved therapies for SCD and apply them to clinical practice

In this activity, three experts provide their perspectives on the clinical manifestations and complications of sickle cell disease (SCD), the multidisciplinary management of these complications, and established and recently approved therapies. The discussion is guided by pre-canvassed questions provided by healthcare professionals involved in the management of patients with SCD.

This activity is jointly provided by USF Health and touchIME. read more

Target Audience

Cardiologists (including paediatric cardiologists), emergency medicine physicians, haematologists (including paediatric haematologists), hospital pharmacists, neurologists, nurse practitioners, paediatricians and primary care physicians involved in the management of sickle cell disease.


USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant relationships are listed below. All individuals not listed have no relevant financial relationships.


Prof. Biree Andemariam discloses: Grants/research support from Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk and Pfizer. Consulting fees from Accordant, Emmaus (Relationship Terminated) and GlaxoSmithKline. Advisory board or panel fees from Afimmune, Agios Pharmaceuticals, Bluebird Bio, Forma Therapeutics, Global Blood Therapeutics, Hemanext, Novartis, Novo Nordisk, Pfizer, Sanofi Genzyme and Vertex Pharmaceuticals.

Prof. Modupe Idowu discloses: Grants/research support from Agios Pharmaceuticals, Alexion, Forma, Global Blood Therapeutics, Novartis, Novo Nordisk and Pfizer. Consulting fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Advisory board or panel fees from Global Blood Therapeutics, Novartis and Novo Nordisk. Speaker’s bureau fees from Global Blood Therapeutics.

Prof. Mark C Walters discloses: Consulting fees from AllCells and BioChip Labs. Advisory board or panel fees from Ensoma and Vertex Pharmaceuticals.

Nurse Planner and Content Reviewer

Amy Patterson MSN, APRN, AOCNS®, BMTCN® discloses the following:
Speakers Bureau: Gilead/Kite (Relationship Terminated).

Pharmacist Reviewer

Rebecca Gonzalez, PharmD BCOP has no relevant financial relationships to disclose.

Touch Medical Contributors

Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.

USF Health Office of Continuing Professional Development and touchIME staff have no financial interests/relationships or affiliations in relation to this activity.

Requirements for Successful Completion

In order to receive credit for this activity, participants must review the content and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.

If you have questions regarding credit please contact



This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through a joint providership of USF Health and touchIME. USF Health is accredited by the ACCME to provide continuing medical education for physicians.

USF Health designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 CreditTM into European CME credit (ECMEC) should contact the UEMS (

Advanced Practice Providers

Physician Assistants may claim a maximum of 0.75 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

The AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM by ACCME-accredited providers. APRNs who participate will receive a certificate of completion commensurate with the extent of their participation.


USF Health is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This knowledge-based program has been approved for 0.75 contact hours (0.75 CEUs). Universal Activity Number (UAN) is as follows: 0230-9999-23-015-H01-P.


USF Health is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

A maximum of 0.75 contact hour may be earned by learners who successfully complete this  continuing professional development activity. USF Health, the accredited provider, acknowledges touchIME as the joint provider in the planning and execution of this CNE activity.

Date of original release: 16 August 2023. Date credits expire: 16 August 2024.

If you have any questions regarding credit please contact

This activity is CE/CME accredited

To obtain contact hours from this activity, please complete this post-activity test.

Claim Credit

Topics covered in this activity

Paediatric Neurology / Stroke / Rare Diseases
  • 1000+ topical and insightful peer-reviewed journal articles
  • 100+ hours of bite-sized congress highlights
  • 10 major therapy areas packed with the latest scientific advances
  • 150+ specialties offering learn-on-the-go medical education
  • + Concise email updates and newsletters so you never miss out
Register For Free Now
Claim Credit
Contemporary insights on the management of sickle cell disease: Focus on complications and recent advances in therapy
0.75 CE/CME credit

Question 1/4
Which of the following factors could exacerbate acute complications in patients with sickle cell disease?

Increased pain sensitivity to cold and heat stimuli and a lower threshold to cold/heat detection is well established in patients with sickle cell disease.1 Cold weather is a common precipitant of acute pain2,3 and patients are advised to keep warm in cold weather.2


  1. Brandow AM, et al. Am J Hematol. 2013;88:37–43.
  2. Rees DC, et al. Blood Rev. 2022;56:100983.
  3. Druye AA, et al. Chronic Illn. 2023 doi:10.1177/17423953231172797.
Question 2/4
You have confirmed a diagnosis of homozygous sickle cell disease (HbSS) in a newborn baby and her mother asks what to expect in terms of complications associated with the disease. You advise that patients with sickle cell disease are at risk of which complication?

Stroke is a recognized major complication of sickle cell disease.1 In a retrospective review of cases between 2016 and 2019, 24/161 (14%) of patients aged ≥18 years with HbSS experienced ischaemic stroke, either symptomatic or silent.1 The most common cause of ischaemic stroke was large vessel occlusion (2.9%).1 In addition, a retrospective analysis of data from the STOP and STOP II clinical trials of patients with homozygous sickle cell disease (HbSS) showed that the risk of haemorrhagic stroke increases with age.2 Screening for stroke risk using transcranial Doppler ultrasound and appropriate management for those at high risk is effective for primary stroke prevention.3


  1. Maduakor C, et al. Front Neurol. 2021;12:744118.
  2. Fox CK, et al. Stroke. 2022;53:e463–6.
  3. Kirkham FJ, Lagunju IA. J Clin Med. 2021;10:4232.
Question 3/4
A 20-year-old patient with confirmed sickle cell disease presents to you in the emergency department with a 2-day history of arm and leg pain that has worsened despite analgesia. He also reports severe pleuritic chest pain and dyspnoea that began today. Which of the following complications would you investigate at this stage?

ACS should be suspected in patients with sickle cell disease presenting with acute respiratory symptoms during a vaso-occlusive crisis. In adults, ACS is characterized by chest pain, dyspnoea, limb pain or a vaso-occlusive crisis in another part of the body; 78% of presentations occur secondary to acute vaso-occlusive pain events. Early diagnosis and management of ACS can reduce mortality and length of hospital stay. Investigation for ACS should include chest imaging for identification of new pulmonary infiltrates and to exclude other respiratory pathology.


ACS, acute chest syndrome.


Friend A, et al. 2023. Available at: (accessed 25 July 2023).

Question 4/4
The phase III HOPE trial investigated the safety and efficacy of voxelotor 1500 mg once daily in patients aged 12–65 years with sickle cell disease. Which of the following was reported with voxelotor treatment, compared with placebo?

In the HOPE trial, a haemoglobin response (increase from baseline of >1.0 g/dL at week 24) was seen in significantly more patients treated with voxelotor 1500 mg than placebo (51 vs 7%; p<0.001). The least squares mean change in haemoglobin level from baseline to week 24 was significantly greater in the voxelotor 1500 mg group than the placebo group (+1.1 vs −0.1 g/dL; p<0.001).


Vichinsky E, et al. N Engl J Med. 2019;381:509–19.

Back to Activity
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72